P06.03 Regression of the Ground Glass Component in Patients with Multifocal Primary Lung Cancers Receiving Pembrolizumab

With the use of HRCT and lung cancer screening program, patients with multifocal primary lung cancers (MPLCs) are becoming a growing population in clinical practice worldwide. It's a rising challenging as no established treatment guideline. Having >= 1 Ground Glass nodule (GGN) or Part-Solid Nodule (PSN) suggests MPLC. Many of these GGN/PSN are pre-/early invasive, or preneoplastic, which is shown to have better preserved immune contexture, and therefore could benefit from immunotherapy (IO). This study is to evaluate potential beneficial effect of IO the pre-/early invasive adenocarcinoma in patients with MPLC.